CTIS2023-504583-42-00招募中1 期
J1I-MC-GZBU? - A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes - J1I-MC-GZB
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be overweight., Have no Type 2 diabetes or has Type 2 diabetes and treated with diet and exercise only with stable doses of up to 3 oral diabetic medications., Have been diagnosed with CKD.
排除标准
- •Have a change in body weight greater than 11 pounds., Have Type 1 Diabetes, Have acute or chronic hepatitis, Have a history of cancer within 5 years before screening.
研究者
相似试验
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)Overweight, Obesity, Type 2 DiabetesCTIS2022-502837-24-00Eli Lilly & Co.1,460
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Obesity, Overweight, Overweight or ObesityCTIS2022-502839-19-00Eli Lilly & Co.3,000